BruhwilerLASchwappachDLB.Safe vincristine use in Switzerland: still a long way to go?J Oncol Pharm Pract. Epub ahead of print 13 March 2019. DOI: 10.1177/1078155219835598.
2.
GilbarPDooleyMBrienJ.Inadvertent intrathecal administration of vincristine: are we fulfilling our roles as oncology pharmacists?J Oncol Pharm Pract2004;
10: 187–189.
3.
StefanouADooleyM.A simple method to eliminate the risk of inadvertent intrathecal vincristine administration.J Clin Oncol2003;
21: 2044–2047.
4.
GilbarP.Inadvertent intrathecal administration of vincristine: has anything changed?J Oncol Pharm Pract2012;
18: 155–157.
5.
GilbarPJDooleyMJ.Review of case reports of inadvertent intrathecal administration of vincristine: recommendations to reduce occurrence.Asia Pacific J Clin Oncol2007;
3: 59–65.
6.
GilbarPJ.Intrathecal chemotherapy. Potential for medication error.Cancer Nurs2014;
37: 299–309.
7.
KresakJLBurtMJRivera-ZengotitaM, et al.
Inadvertent intrathecal vincristine administration with widespread axonal injury demonstrated by amyloid precursor protein immunohistochemistry.Acad Forensic Pathol2014;
4: 563–566.
8.
SahaASIslamFBhattacharyaS, et al.
Clinical presentation of inadvertent intrathecal vincristine masquerading as Guillain-Barre syndrome.Indian J Hematol Blood Transfus2016;
32: S59–S61.
9.
Dabrowska-WojciakI.The death of an infant after the unfortunate intrathecal injection of vincristine.Clin Pract2018;
15: 438–441.
10.
GilbarPJCarringtonCV.The incidence of extravasation of vinca alkaloids supplied in syringes or mini-bags.J Oncol Pharm Pract2006;
12: 113–118.
11.
GilbarPChambersCRLarissaM.Medication safety and the administration of intravenous vincristine: International survey of oncology pharmacists.J Oncol Pharm Pract2015;
21: 10–18.
12.
NurgatZASmytheMAl-JedaiA, et al.
Introduction of mini-bags and an assessment of the subsequent risk of extravasation.J Oncol Pharm Pract2015;
21: 339–347.
13.
EnerRAMeglartherySBStylerM.Extravasation of systemic hemato-oncological therapies.Ann Oncol2004;
15: 858–862.
14.
GreenallJShastayAVaidaAJ, et al.
Establishing an international baseline for medication safety in oncology: findings from the 2102 ISMP International Medication Safety Self Assessment® for Oncology.J Oncol Pharm Pract2015;
21: 26–35.
15.
KurgatEKWeruIWataD, et al.
Proactive risk assessment of vincristine use process in a teaching and referral hospital in Kenya and the implications.J Oncol Pharm Pract. Epub ahead of print 2 September 2019. DOI: 10.1177/1078155219869439.
